NCT02377752 2021-02-17A Study of Olaratumab in Japanese Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed25 enrolled 19 charts
NCT01199822 2017-04-14Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsEli Lilly and CompanyPhase 1 Completed16 enrolled 15 charts